Core Viewpoint - The approval of three innovative products by Hangzhou Jialiang Medical Technology Co., Ltd. marks a significant breakthrough in domestic MRI-guided neurosurgical minimally invasive treatment equipment, enhancing treatment options for drug-resistant epilepsy patients [2][5][18]. Product Approval Information - On October 29, 2025, the National Medical Products Administration approved three innovative products: "MRI Monitoring Semiconductor Laser Treatment Device," "Disposable Laser Fiber Kit," and "Stereotactic Surgery Planning Software" [2][3]. - The total number of innovative medical devices approved in China has reached 377 [2]. Product Composition and Functionality - The MRI Monitoring Semiconductor Laser Treatment Device consists of a main unit and accessories, while the Disposable Laser Fiber Kit includes a medical fiber catheter component and a cooling water pipe. The Stereotactic Surgery Planning Software comprises an installation USB drive and a key [4][13]. - These products are designed for laser ablation treatment of focal lesions in drug-resistant epilepsy patients, utilizing MRI imaging for precise monitoring during surgery, thereby minimizing damage to normal brain tissue and preserving cognitive function [4][11]. Company Overview - Hangzhou Jialiang Medical Technology Co., Ltd. was established in 2020 and focuses on the industrialization of cutting-edge technologies in brain science and neurosurgery. The company has developed three major technology platforms: brain-machine control, medical lasers, and brain-machine chips [8]. - The company has established dual headquarters in China and Singapore, with a GMP production base and a professional R&D center, promoting independent innovation and global application of high-end neurosurgical systems [8]. Core Product Layout - The LaserRO™ MRI-guided laser ablation minimally invasive surgical system is a key component of the company's offerings, combining real-time MRI monitoring with laser fiber technology for targeted ablation of diseased tissue [9][11]. - The system is designed to provide a new treatment option for drug-resistant epilepsy patients, significantly reducing damage to normal brain tissue and enhancing cognitive function preservation [11][18]. Conclusion - The approval of these three innovative products opens a new technological dimension for domestic neurosurgical equipment, integrating real-time MRI monitoring, precise energy delivery, and surgical path planning, thus enhancing the treatment of complex brain diseases [18]. - This innovation not only fills technological gaps in individual products but also establishes a clinical system that integrates imaging, energy, and algorithms, positioning brain science as a new growth driver for domestic high-end medical device innovation [18].

Core Viewpoint - The National Medical Products Administration has approved three innovative products from Hangzhou Jialiang Medical Technology Co., Ltd., including a magnetic resonance monitoring semiconductor laser treatment device, a disposable laser fiber kit, and a stereotactic surgical planning software [1] Group 1: Product Details - The magnetic resonance monitoring semiconductor laser treatment device consists of a main unit and accessories [1] - The disposable laser fiber kit includes a medical fiber catheter component and a cooling water pipe [1] - The stereotactic surgical planning software is composed of a USB drive and a key [1] Group 2: Application and Benefits - The magnetic resonance monitoring semiconductor laser treatment device and the disposable laser fiber kit are designed for laser treatment of drug-resistant epilepsy patients with focal seizures and clear epileptogenic zones [1] - The stereotactic surgical planning software is used in conjunction with the laser treatment device for planning head stereotactic surgeries [1] - The products aim to minimize damage to normal brain tissue during surgery, thereby better preserving cognitive function [1] Group 3: Regulatory Oversight - The drug supervision authority will enhance post-market supervision of the approved products to ensure patient safety [1]